Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigations

In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl

Sangram Nag, Patrik Fazio, Lutz Lehmann, Georg Kettschau, Tobias Heinrich, Andrea Thiele, Marie Svedberg, Nahid Amini, Samira Leesch, Ana M. Catafau, Jonas Hannestad, Andrea Varrone and Christer Halldin
Journal of Nuclear Medicine February 2016, 57 (2) 315-320; DOI: https://doi.org/10.2967/jnumed.115.161083
Sangram Nag
1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrik Fazio
1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lutz Lehmann
2Bayer HealthCare AG, Global Drug Discovery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Kettschau
2Bayer HealthCare AG, Global Drug Discovery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Heinrich
2Bayer HealthCare AG, Global Drug Discovery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Thiele
2Bayer HealthCare AG, Global Drug Discovery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Svedberg
1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahid Amini
1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samira Leesch
3Piramal Imaging GmbH, Berlin, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana M. Catafau
3Piramal Imaging GmbH, Berlin, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Hannestad
4UCB Pharma, Braine-l’Alleud, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Varrone
1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christer Halldin
1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 57 no. 2 315-320
DOI 
https://doi.org/10.2967/jnumed.115.161083
PubMed 
26585057

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 19, 2015
  • Accepted for publication October 19, 2015
  • Published online February 1, 2016.

Article Versions

  • previous version (November 19, 2015 - 06:22).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Sangram Nag1,
  2. Patrik Fazio1,
  3. Lutz Lehmann2,
  4. Georg Kettschau2,
  5. Tobias Heinrich2,
  6. Andrea Thiele2,
  7. Marie Svedberg1,
  8. Nahid Amini1,
  9. Samira Leesch3,
  10. Ana M. Catafau3,
  11. Jonas Hannestad4,
  12. Andrea Varrone1 and
  13. Christer Halldin1
  1. 1Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  2. 2Bayer HealthCare AG, Global Drug Discovery, Berlin, Germany
  3. 3Piramal Imaging GmbH, Berlin, Germany; and
  4. 4UCB Pharma, Braine-l’Alleud, Belgium
  1. For correspondence or reprints contact: Sangram Nag, Department of Clinical Neuroscience, Karolinska Hospital, Karolinska Institutet, S-17176, Stockholm, Sweden. E-mail: sangram.nag{at}ki.se
View Full Text

Statistics from Altmetric.com

Cited By...

  • 46 Citations
  • 55 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Deuterium‐ and Tritium‐Labelled Compounds: Applications in the Life Sciences
    Jens Atzrodt, Volker Derdau, William J. Kerr, Marc Reid
    Angewandte Chemie International Edition 2018 57 7
  • Applications of Deuterium in Medicinal Chemistry
    Tracey Pirali, Marta Serafini, Sarah Cargnin, Armando A. Genazzani
    Journal of Medicinal Chemistry 2019 62 11
  • Neuroinflammation in psychiatric disorders: PET imaging and promising new targets
    Jeffrey H Meyer, Simon Cervenka, Min-Jeong Kim, William C Kreisl, Ioline D Henter, Robert B Innis
    The Lancet Psychiatry 2020 7 12
  • Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
    Vidya Narayanaswami, Kenneth Dahl, Vadim Bernard-Gauthier, Lee Josephson, Paul Cumming, Neil Vasdev
    Molecular Imaging 2018 17
  • Deuterium‐ und tritiummarkierte Verbindungen: Anwendungen in den modernen Biowissenschaften
    Jens Atzrodt, Volker Derdau, William J. Kerr, Marc Reid
    Angewandte Chemie 2018 130 7
  • PET Imaging of Neuroinflammation in Alzheimer’s Disease
    Rong Zhou, Bin Ji, Yanyan Kong, Limei Qin, Wuwei Ren, Yihui Guan, Ruiqing Ni
    Frontiers in Immunology 2021 12
  • 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging
    Ryuichi Harada, Yoshimi Hayakawa, Michinori Ezura, Pradith Lerdsirisuk, Yiqing Du, Yoichi Ishikawa, Ren Iwata, Miho Shidahara, Aiko Ishiki, Akio Kikuchi, Hiroyuki Arai, Yukitsuka Kudo, Kazuhiko Yanai, Shozo Furumoto, Nobuyuki Okamura
    Journal of Nuclear Medicine 2021 62 2
  • Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder
    Sho Moriguchi, Alan A. Wilson, Laura Miler, Pablo M. Rusjan, Neil Vasdev, Stephen J. Kish, Grazyna Rajkowska, Junming Wang, Michael Bagby, Romina Mizrahi, Ben Varughese, Sylvain Houle, Jeffrey H. Meyer
    JAMA Psychiatry 2019 76 6
  • Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
    Aiko Ishiki, Ryuichi Harada, Hideaki Kai, Naomi Sato, Tomoko Totsune, Naoki Tomita, Shoichi Watanuki, Kotaro Hiraoka, Yoichi Ishikawa, Yoshihito Funaki, Ren Iwata, Shozo Furumoto, Manabu Tashiro, Hironobu Sasano, Tetsuyuki Kitamoto, Yukitsuka Kudo, Kazuhiko Yanai, Katsutoshi Furukawa, Nobuyuki Okamura, Hiroyuki Arai
    Acta Neuropathologica Communications 2018 6 1
  • Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?
    Paolo Guglielmi, Simone Carradori, Alessandra Ammazzalorso, Daniela Secci
    Expert Opinion on Drug Discovery 2019 14 10

Article usage

Article usage: November 2015 to April 2025

AbstractFullPdf
Nov 2015232041
Dec 2015196029
Jan 2016150021
Feb 20166671146
Mar 20161421223
Apr 20161201314
May 201680916
Jun 201655713
Jul 201650612
Aug 2016741220
Sep 2016481325
Oct 2016661830
Nov 2016391222
Dec 2016622025
Jan 2017794142
Feb 2017432821
Mar 2017343927
Apr 2017481714
May 2017461413
Jun 2017503021
Jul 2017421511
Aug 2017422435
Sep 2017292426
Oct 2017512819
Nov 2017491821
Dec 2017292215
Jan 2018502413
Feb 2018281815
Mar 2018542117
Apr 2018411813
May 2018361314
Jun 2018241412
Jul 201819610
Aug 20182658
Sep 2018332220
Oct 2018262626
Nov 201824920
Dec 2018101319
Jan 2019291211
Feb 2019211412
Mar 2019331313
Apr 2019231619
May 201991624
Jun 2019152124
Jul 2019291523
Aug 2019331620
Sep 201917118
Oct 2019332316
Nov 2019161424
Dec 2019272012
Jan 2020211623
Feb 2020101722
Mar 2020162219
Apr 202091615
May 202092723
Jun 2020161213
Jul 202017124
Aug 202083810
Sep 2020131315
Oct 2020182113
Nov 2020161611
Dec 20201285
Jan 202173624
Feb 202172023
Mar 202144921
Apr 202163224
May 202122915
Jun 202141916
Jul 202162627
Aug 202173822
Sep 202172821
Oct 202131933
Nov 202141935
Dec 202142621
Jan 202271921
Feb 202253114
Mar 202243612
Apr 202261714
May 202282818
Jun 2022132324
Jul 202242311
Aug 202232732
Sep 202272131
Oct 202232728
Nov 202251945
Dec 202212114
Jan 202362613
Feb 2023397
Mar 2023203029
Apr 202322326
May 202352126
Jun 202312217
Jul 202332521
Aug 202371710
Sep 202372117
Oct 202322215
Nov 202371814
Dec 202353014
Jan 202482013
Feb 202442614
Mar 202471157
Apr 20241011537
May 202443113
Jun 202473025
Jul 202452227
Aug 2024243628
Sep 2024143322
Oct 202482719
Nov 202433521
Dec 202482916
Jan 202563124
Feb 202555528
Mar 202552921
Apr 2025148039
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (2)
Journal of Nuclear Medicine
Vol. 57, Issue 2
February 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl
Sangram Nag, Patrik Fazio, Lutz Lehmann, Georg Kettschau, Tobias Heinrich, Andrea Thiele, Marie Svedberg, Nahid Amini, Samira Leesch, Ana M. Catafau, Jonas Hannestad, Andrea Varrone, Christer Halldin
Journal of Nuclear Medicine Feb 2016, 57 (2) 315-320; DOI: 10.2967/jnumed.115.161083

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl
Sangram Nag, Patrik Fazio, Lutz Lehmann, Georg Kettschau, Tobias Heinrich, Andrea Thiele, Marie Svedberg, Nahid Amini, Samira Leesch, Ana M. Catafau, Jonas Hannestad, Andrea Varrone, Christer Halldin
Journal of Nuclear Medicine Feb 2016, 57 (2) 315-320; DOI: 10.2967/jnumed.115.161083
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging
  • Google Scholar

More in this TOC Section

  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
  • Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy
  • Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology
Show more Basic Science Investigations

Similar Articles

Keywords

  • 18F-fluorodeprenyl-D2
  • Monoamine oxidase
  • monkey
  • PET
SNMMI

© 2025 SNMMI

Powered by HighWire